Autopsy report · NCT01580618

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

“Unable to accrue patients at a reasonable rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 8 months after it had already started.
• Ran for about 3 years 8 months before it stopped.
• 20 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Kaiser Permanente

Sponsor type

University, hospital or other

Conditions

Pleural Effusion

Interventions

normal saline; TNK (Tenecteplase)

Participants

20

Sites

1

Countries

United States

Trials that died the same way

• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (79% match in meaning)
• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (77% match in meaning)
• Dose-adjusted EPOCH-R in MYC Positive DLBCL
  “Poor accrual of eligible patients” (77% match in meaning)
• A Study on the Angioarchitecture of Hepatocellular Carcinoma
  “Poor patient accrual” (76% match in meaning)
• Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
  “Lack of feasibility to accrue patients in allotted time.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.